HENDERSON, Nev.–(BUSINESS WIRE)–3PEA International, Inc. (OTCBB:TPNL) (OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, is pleased to announce that B Positive National Blood Services has selected 3PEA International to provide its comprehensive PaySign® prepaid solution as its exclusive plasma donor payment solution.
The comprehensive PaySign prepaid solution includes the “PaySign Connect,” an intuitive, easy-to-use, fully tokenized platform tailored to the unique requirements of the plasma collection industry. The PaySign Connect portal can run as either a standalone, web-based solution or can be fully integrated with existing donor management systems. The PaySign Connect portal securely stores donor information and donation history, including volume range, weight group, donor type, donation frequency, notes, and other pertinent fields. 3PEA’s customized reports simplify accounting procedures, reduce administrative costs, streamline operations, increase efficiency, and help maintain compliance requirements. Adding a dimension far beyond simple financial accounting and funds reconciliation, the PaySign solution provides a level of business analytics previously unavailable from existing payment card programs.
The PaySign prepaid solution also includes the PaySign Visa® Prepaid Card that can be used anywhere Visa is accepted. Plasma donors can access their account information using the PaySign kiosk located at any B Positive donation center, a dedicated cardholder website, an Interactive Voice Response (IVR) system, SMS alerts, two-way SMS, or by calling 3PEA’s in-house bilingual customer service center, staffed 24/7/365. The customized PaySign prepaid solution was built with the goals of improving donor retention rates and overall donor satisfaction.
“We are pleased that PaySign has been chosen by B Positive as their exclusive donor payment solution,” said Mark Newcomer, Chairman and CEO of 3PEA. “As we expand our presence in the Plasma donation industry, we remain committed to providing our customers the highest quality payment solutions available.”
“The PaySign solution delivers the features B Positive requires in a prepaid donor payment solution,” explained Benjamin S. Ruder, Chief Executive Officer of B Positive National Blood Services. “3PEA has earned an excellent reputation and we look forward to implementing the PaySign solution.”
About 3PEA International
3PEA International (OTCBB:TPNL) is an experienced and trusted prepaid debit card payment solutions provider as well as an integrated payment processor that has millions of prepaid debit cards in its portfolio. Through its PaySign brand, 3PEA designs and develops payment solutions, prepaid card programs, and customized payment services. 3PEA manages programs for many of the world’s largest pharmaceutical manufacturers with copay assistance products designed to maximize new patient acquisition, retention, and adherence. 3PEA’s corporate incentive prepaid cards are changing the way corporations reward, motivate, and engage their current and potential customers, employees, and agents. 3PEA’s customizable prepaid solutions offer significant cost savings while improving brand recognition and customer loyalty. 3PEA’s customers include healthcare companies, major pharmaceutical companies and source plasma providers, large multinationals, prestigious universities, and social media companies. PaySign is a registered trademark of 3PEA Technologies, Inc. in the United States and other countries. For more information visit us at www.paysign.com or follow us on LinkedIn, Twitter and Facebook.
About B Positive National Blood Services
B Positive National Blood Services, LLC was established in 2010 with the purpose of collecting high quality plasma and other blood products to be used in the creation of life-saving therapies. B Positive’s is committed to a high level of safety and quality of service as a first priority for their donors. The company prides itself in meeting or exceeding all regulations and guidelines outlined by the governing bodies in the blood collection industry. The company’s policies are based upon the requirements set forth by the Food and Drug Administration (FDA), the Plasma Protein Therapeutics Association (PPTA), the Occupational Safety and Health Administration (OSHA), and several other federal, state and local regulations.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. 3PEA undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Brian Polan, VP Corporate Finance
B Positive National Blood Services:
Benjamin S. Ruder, CEO
3PEA IR Firm:
MZ North America
Ted Haberfield, President